Background: Evidence on the progress of disease severity in Multiple Sclerosis (MS) is generally limited in scope. Objectives: To examine the course of a broad spectrum of MS-related disabilities and quality of life (QOL) in relation to disease severity, and responsiveness of the Multiple Sclerosis Impact Profile (MSIP). Methods: The mortality rate was calculated after checking the national population register for vital status of the initial cohort. We performed a longitudinal study among 245 patients with MS attending the Groningen MS Center in the Netherlands. We assessed these patients in 2004 and 2009 using a postal survey including the MSIP to evaluate disabilities, the World Health Organization Quality of Life-Abbreviation version (WH...
AbstractBackgroundMost people with multiple sclerosis (PwMS) experience progressively worsening disa...
BACKGROUND: In the past two decades the widespread use of disease modifying drugs with moderate to s...
BACKGROUND: There is no consensus method for determining progression of disability in patients with ...
Background: Evidence on the progress of disease severity in Multiple Sclerosis (MS) is generally lim...
Background: Evidence on the progress of disease severity in Multiple Sclerosis (MS) is generally lim...
Objective People with Multiple Sclerosis (MS) experience lower levels of quality of life (QOL) than ...
Abstract Background Progression in disability as measured by increase in the Expanded Disability Sta...
International audienceBackground: Responsiveness, defined as the ability to detect a meaningful chan...
Objective: To determine the value of health-related quality of life (HRQoL) to predict change in dis...
OBJECTIVES The aim of this study was to assess the quality of life (QoL) of patients with multiple s...
Background: In patients with multiple sclerosis (MS), the natural history of the disease is of consi...
Background: Quantifying the clinical impact of multiple sclerosis (MS) is one of the most important ...
Background: There is no consensus method for determining progression of disability in patients with ...
Objective—To assess the quality of life (QoL) of patients with multiple sclerosis in France, Germany...
Background: There is no consensus method for determining progression of disability in patients with ...
AbstractBackgroundMost people with multiple sclerosis (PwMS) experience progressively worsening disa...
BACKGROUND: In the past two decades the widespread use of disease modifying drugs with moderate to s...
BACKGROUND: There is no consensus method for determining progression of disability in patients with ...
Background: Evidence on the progress of disease severity in Multiple Sclerosis (MS) is generally lim...
Background: Evidence on the progress of disease severity in Multiple Sclerosis (MS) is generally lim...
Objective People with Multiple Sclerosis (MS) experience lower levels of quality of life (QOL) than ...
Abstract Background Progression in disability as measured by increase in the Expanded Disability Sta...
International audienceBackground: Responsiveness, defined as the ability to detect a meaningful chan...
Objective: To determine the value of health-related quality of life (HRQoL) to predict change in dis...
OBJECTIVES The aim of this study was to assess the quality of life (QoL) of patients with multiple s...
Background: In patients with multiple sclerosis (MS), the natural history of the disease is of consi...
Background: Quantifying the clinical impact of multiple sclerosis (MS) is one of the most important ...
Background: There is no consensus method for determining progression of disability in patients with ...
Objective—To assess the quality of life (QoL) of patients with multiple sclerosis in France, Germany...
Background: There is no consensus method for determining progression of disability in patients with ...
AbstractBackgroundMost people with multiple sclerosis (PwMS) experience progressively worsening disa...
BACKGROUND: In the past two decades the widespread use of disease modifying drugs with moderate to s...
BACKGROUND: There is no consensus method for determining progression of disability in patients with ...